| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to know before the announcement.
Analysts estimate that Cyclacel Pharmaceuticals will report an earnings per share (EPS) of $-5.89.
Cyclacel Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Last quarter the company missed EPS by $1.95, which was followed by a 35.54% drop in the share price the next day.
Here's a look at Cyclacel Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -5.40 | -7.5 | -9.90 | -7.2 |
| EPS Actual | -7.35 | -6.6 | -7.05 | -9 |
| Price Change % | -36.0% | -0.0% | -1.0% | -3.0% |
Shares of Cyclacel Pharmaceuticals were trading at $2.43 as of March 15. Over the last 52-week period, shares are down 73.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CYCC
